

blood

Prepublished online March 12, 2014;
doi:10.1182/blood-2013-12-545087

HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy

David C. Fajgenbaum, Frits van Rhee and Christopher S. Nabel

Information about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml>

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.

Copyright 2011 by The American Society of Hematology; all rights reserved.



HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy

David C. Fajgenbaum,¹ Frits van Rhee,² and Christopher S. Nabel³

¹Center for Orphan Disease Research and Therapy, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

²Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and ³Department of Medicine, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Multicentric Castleman disease (MCD) describes a heterogeneous group of disorders involving proliferation of morphologically benign lymphocytes due to excessive proinflammatory hypercytokinemia, most notably of interleukin-6. Patients demonstrate intense episodes of systemic inflammatory symptoms, polyclonal lymphocyte and plasma cell proliferation, autoimmune manifestations, and organ system impairment. Human herpes virus-8 (HHV-8) drives the hypercytokinemia in all HIV-positive patients and some HIV-negative patients. There is

also a group of HIV-negative and HHV-8-negative patients with unknown etiology and pathophysiology, which we propose referring to as idiopathic MCD (iMCD). Here, we synthesize what is known about iMCD pathogenesis, present a new subclassification system, and propose a model of iMCD pathogenesis. MCD should be subdivided into HHV-8-associated MCD and HHV-8-negative MCD or iMCD. The lymphocyte proliferation, histopathology, and systemic features in iMCD are secondary to hypercytokinemia, which can occur with several other diseases. We

propose that 1 or more of the following 3 candidate processes may drive iMCD hypercytokinemia: systemic inflammatory disease mechanisms via autoantibodies or inflammatory gene mutations, paraneoplastic syndrome mechanisms via ectopic cytokine secretion, and/or a non-HHV-8 virus. Urgent priorities include elucidating the process driving iMCD hypercytokinemia, identifying the hypercytokine-secreting cell, developing consensus criteria for diagnosis, and building a patient registry to track cases. (*Blood*. 2014;00(00):1-10)

Introduction

Multicentric Castleman disease (MCD) is a rare and poorly understood disorder that straddles the intersections of hematology, oncology, rheumatology, and virology and can be fatal if improperly treated. MCD describes a heterogeneous group of disorders with various etiologies that demonstrate episodic systemic inflammatory symptoms, reactive proliferation of morphologically benign lymphocytes, and multiple organ system impairment as a result of excessive interleukin-6 (IL-6) and other proinflammatory cytokines.¹⁻³ The population incidence has not been established; a recent study estimates 4353 new cases of “Castleman disease” per year in the United States, which we approximate to include 1000 cases of MCD.⁴

Human herpes virus-8 (HHV-8) is the well-established cause of the hypercytokinemia (highly elevated levels of cytokines) in all HIV-positive MCD patients and in some HIV-negative patients.⁵ Among these HHV-8-associated MCD cases, HIV infection or another cause of immunodeficiency enables HHV-8 to escape from host immune control, lytically replicate in lymph node plasmablasts, and signal the release of viral IL-6, human IL-6, and several other proinflammatory proteins.^{6,7} These proinflammatory proteins induce B-cell and plasma cell proliferation, vascular endothelial growth factor (VEGF) secretion and angiogenesis, and an acute phase reaction.⁸ There is also a group of HIV-negative and HHV-8-negative MCD patients whose disease we propose referring to as idiopathic MCD (iMCD). The etiology of iMCD proinflammatory hypercytokinemia is not known and may be viral, inflammatory, or neoplastic.^{5,6} MCD has been historically classified based on HIV status, but this has caused confusion because HHV-8 drives all HIV-positive MCD

cases and some HIV-negative MCD cases. HIV infection merely results in immunodeficiency, which can occur through multiple other etiologies, making the patient more vulnerable to HHV-8 replication and concomitant viral-dependent hypercytokinemia. HHV-8 was detected in the lymph node or blood in >90 of the 999 HIV-negative MCD cases identified in a recent systematic literature search. HHV-8 was tested for, but not detected, in ~600 of those MCD cases (D.C.F., C.S.N., and Amy Y. Liu, unpublished data, 2014). Building on a recent paper by Dossier et al indicating that all HHV-8-associated MCD cases may be considered as a single clinicopathological entity regardless of HIV status, we recommend classifying MCD based on HHV-8 status and believe this will decrease heterogeneity in future studies (Figure 1).⁶

Although no survival data currently exist for iMCD, a 2011 systematic literature review identified a 45.7% 3-year disease-free survival rate among 84 HIV-negative, HHV-8 unknown MCD case reports, and 45.4% of these patients died of MCD prior to publication of their respective case reports.⁹ The 10-year overall survival rate was ~40% in a 2012 series of 60 HHV-8 unknown MCD cases, up from 13% in a 1993 series of 38 patients.^{10,11} Further progress in long-term outcome is anticipated with the advent of antibodies targeting the IL-6 signaling cascade, such as tocilizumab and siltuximab.^{12,13} However, these antibodies require long-term administration and are not effective in all patients. We conducted this comprehensive review to facilitate the continued discovery of iMCD pathogenesis and novel therapeutic targets. Herein, we define the entity of iMCD and describe its pathologic and clinical features.

Submitted December 17, 2013; accepted March 3, 2014. Prepublished online as *Blood* First Edition paper, March 12, 2014; DOI 10.1182/blood-2013-12-545087.

D.C.F., F.v.R., and C.S.N. contributed equally to this paper.

© 2014 by The American Society of Hematology




Figure 1. MCD subclassification. (A) The traditional classification of MCD has been distinguished by HIV status. However, HHV-8 is responsible for cases of both HIV-positive and HIV-negative MCD. Therefore, HIV-based classification does not adequately distinguish the driving factor of MCD pathogenesis. (B) The newly proposed classification distinguishes MCD based on HHV-8-status, which is more accurate based on pathogenesis and response to treatments.

Further, we present the state of knowledge regarding the pathogenesis of iMCD and propose several mechanisms that may be responsible for iMCD hypercytokinemia. Finally, we discuss the rationale for current and future therapies for iMCD and briefly outline important next steps for research.

Pathological and clinical features

No official criteria currently exist for iMCD diagnosis, and no disease-specific histopathologic features or biomarkers have been identified. Diagnosis is made when Castleman lymph node histopathologic features and clinical correlates are observed and all other infectious, autoimmune, and neoplastic diseases known to demonstrate these features have been systematically excluded (Table 1; Figure 2).¹⁴ We propose that iMCD cases should have (1) negative HIV serology and (2) no replicating HHV-8 virus detectable by polymerase chain reaction in the peripheral blood or negative staining for HHV-8 latent nuclear antigen in lymph node tissue. HHV-8 latent nuclear antigen staining and HHV-8 by polymerase chain reaction are positive in nearly 100% of HHV-8-associated cases during acute episodes.^{15,16}

Castleman disease is named for Benjamin Castleman, who first described the characteristic histopathological findings of angio-follicular lymph node hyperplasia in a localized lymph node region in 1954.¹⁷ In 1974, Gaba et al described the first cases of this histopathology in multiple lymph nodes.¹⁸ Castleman disease has since been separated into unicentric (UCD) and MCD, although some authors only report “Castleman disease,” which should be avoided. Although not the subject of this review, UCD is often asymptomatic and has a high cure rate with surgical excision of the enlarged lymph node.¹⁹ MCD histopathological features can be divided into 4 variants: hyaline-vascular (HV), plasma cell (PC), mixed, and plasmablastic. HV is characterized by widened mantle zones composed of concentric rings of small lymphocytes in an “onion skin” pattern around small atrophic germinal centers with penetrating hyalinized vessels and dysplastic follicular dendritic cells (FDCs).¹ In PC, the germinal centers are hyperplastic rather than atrophic, the interfollicular region contains sheets of plasma cells and vascular proliferations, the FDC network is normal, and there is preserved lymph node architecture.²⁰ The mixed variant displays features of both HV and PC. The reliability and significance of these variants is unclear, as there are reports of transitions between HV and PC variants on subsequent biopsies, as well as the simultaneous presence of both types at separate sites within the same patient.²¹ Three recent studies reported 17% to 49% HV, 46% to 77% PC, and 4% to 20% mixed pathology among 198 HIV-negative MCD cases.^{9,10,12} Of note, these histopathological

features are nonspecific, reactive to hypercytokinemia from any source in the body, and can be found in several infectious, rheumatologic, and neoplastic diseases (Table 1).^{3,22-24} Thus, iMCD lymph nodes should not be considered tumors. The plasmablastic variant is only found in HHV-8-associated MCD and will not be discussed.

Immunoglobulin and T-cell receptor gene studies indicate that the lymphocyte proliferation in iMCD is polyclonal and thus reactive to hypercytokinemia.²⁵ The discovery of monoclonal lymphocytes should raise the possibility of an alternative malignancy.²⁶ Rare cases of cytogenetic aberrations and light chain restriction have been described, including 1 report describing a translocation involving the IL-6 gene.^{20,27} Chang et al recently identified monoclonality in 19 of 25 HV-UCD cases, 2 of 2 PC-UCD, 3 of 3 HV-iMCD cases, and 1 of 1 PC-iMCD cases in a study of 31 female patients. Immunoglobulin and T-cell receptor genes were in germ-line status in 3 of 4 iMCD cases, indicating that stromal cells must be the monoclonal cells in those cases. The authors concluded that most cases of HV-UCD and HV-MCD are monoclonal proliferations, most likely of stromal actin-positive myoid cells and FDCs.²⁸ Further investigations of stromal cell monoclonality in iMCD are needed.

iMCD can occur at any age, but it typically affects individuals in the fourth and fifth decades of life, and it is more frequent in men than women.^{10,19} The clinical spectrum ranges from waxing and waning

Table 1. Diseases that can demonstrate iMCD-like histopathology and diseases reported to cooccur with iMCD

Neoplastic	Inflammatory	Infectious/toxin ingestion
iMCD-like histopathology		
Non-Hodgkin lymphoma	Systemic lupus erythematosus	Epstein-Barr virus
Cutaneous lymphoma	Rheumatoid arthritis	HIV
Hodgkin lymphoma	Sjogren syndrome	Hydrochloride ingestion
Cardiac myxoma	Relapsing polychondritis	
Multiple myeloma	Systemic IGG4 plasmacytic syndrome	
Clear cell meningioma	Systemic/cutaneous plasmacytosis	
Choroid meningioma		
Giant cell carcinoma of lung		
Calcifying fibrous pseudotumor		
Inflammatory myofibroblastic tumor		
Cooccur with iMCD		
POEMS syndrome	Adult onset Still's disease	Human herpes virus 6
Paraneoplastic pemphigus	Systemic juvenile idiopathic arthritis	Hepatitis b virus
Melanoma	Sarcoidosis	Toxoplasma
Angioimmunoblastic T-cell lymphoma	Amyloidosis	<i>Mycobacterium tuberculosis</i>
Indolent T-lymphoblastic proliferation	Pure red cell aplasia	Cytomegalovirus
Inflammatory hepatocellular adenoma	Acquired factor VIII deficiency	Toxoplasma
	Myasthenia gravis	
	Familial mediterranean fever	
	Glomerulonephritides	




Figure 2. Diseases with Castleman-like lymph node histopathological features. Angiofollicular lymph node hyperplasia, or Castleman-like histopathological features are seen in unicentric and multicentric Castleman disease. These changes are nonspecific and can also be seen with other autoimmune diseases, malignancies, and infections. Disease states are listed in blue, and histopathological findings are listed in pink.

mild lymphadenopathy with B-symptoms to more severe cases involving intense inflammation, hepatosplenomegaly, vascular leak syndrome with anasarca, pleural effusions, and ascites, organ failure, and even death.^{10,29} Acute episodes can display significant clinical overlap with acute viral illnesses and autoimmune diseases.³ Skin involvement in the form of cherry hemangiomas often occurs.³⁰ Clinical differences can be observed between ethnic groups. Patients of Asian descent often display large violaceous skin lesions and interstitial pneumonitis,^{13,31} and Polynesian patients demonstrate a mild clinical course despite significant biochemical derangements.³²

Laboratory findings commonly include anemia, elevated erythrocyte sedimentation rate, C-reactive protein, IL-6, VEGF, and fibrinogen; positive anti-nuclear antibody, anti-erythrocyte autoantibodies, and anti-platelet antibodies; and proteinuria, hypoalbuminemia, polyclonal marrow plasmacytosis, polyclonal hypergammaglobulinemia, and thrombocytosis or thrombocytopenia.¹⁴ Kawabata et al recently described a group of iMCD patients in Japan with thrombocytopenia, ascites, reticuline fibrosis, renal dysfunction, and organomegaly (TAFRO syndrome), which demonstrate milder lymphadenopathy, mixed or HV histopathology, severe thrombocytopenia, normal or mildly elevated levels of IL-6 and VEGF, the presence of autoantibodies, severe anasarca, and normal immunoglobulin levels.³³ Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, a paraneoplastic syndrome involving VEGF and other cytokine secretion by malignant plasma cells, can demonstrate significant clinical and histopathological overlap with iMCD, such as volume overload, renal disease, and cherry hemangiomas. Thirty-seven percent to 60% of POEMS cases have elements of Castleman disease histopathology, and many patients with CD may also demonstrate POEMS features, including IgA monoclonal gammopathy of undetermined significance.^{14,34,35} We suspect that the frequent association between POEMS and iMCD may occur, because the malignant, POEMS-driving plasma cells secrete cytokines that also cause iMCD-like reactive lymph node changes, rather than separate diseases cooccurring. There are also a host of other neoplastic, infectious, and autoimmune diseases reported to cooccur with iMCD, for which it is difficult to differentiate or determine a causative relationship from limited case reports (Table 1).³

Pathogenesis

The mechanisms responsible for iMCD pathogenesis are poorly understood and may differ between cohorts of patients. In the following paragraphs, we summarize the most important observations regarding iMCD pathogenesis and present a model (Figure 3).

Candidate etiological triggers

Candidate etiological triggers from limited numbers of case reports and studies include a somatic chromosomal abnormality in non-neoplastic cells (eg, translocation in the IL-6 gene), germ-line genetic mutation in an inflammatory gene (eg, IL-6 promoter polymorphism), ectopic IL-6 release by malignant tumor cells, autoantibody antigenic stimulation, and infectious agents.^{3,27,36,37} Epstein-Barr virus (EBV), HHV-6, hepatitis B virus, cytomegalovirus, toxoplasma, and *Mycobacterium tuberculosis* have each been reported to cooccur in ≥ 1 case of iMCD, but most iMCD cases do not report an associated infectious agent.³⁸⁻⁴³ These infections may be pathologic, coincidental, or secondary to iMCD-related immune dysfunction.

Key iMCD cytokines

Human and animal studies have demonstrated IL-6's role as a common mediator of iMCD symptomatology, histopathology, and pathogenesis. Symptoms typically wax and wane in accordance with serum IL-6 levels, which are often highly elevated in iMCD.¹⁴ Interruption of the IL-6 signaling cascade with anti-IL-6 or anti-IL-6 receptor monoclonal antibodies (mAb) often ameliorates iMCD symptoms and can lead to lymph node involution.^{13,44} Furthermore, human IL-6 transgenic mice and mice infected with an IL-6-expressing recombinant retrovirus develop an iMCD-like syndrome, which also improves with anti-IL-6 receptor mAb administration⁴⁵⁻⁴⁷ (Table 2, murine models of MCD). Patients with IL-6 secreting hematologic and solid malignancies develop iMCD-like histopathology and symptomatology, which resolve with IL-6 blockade or tumor excision.^{48,49} Finally, the administration of pharmacologic doses of recombinant IL-6 to humans can lead to an iMCD-like syndrome.⁵⁰ These findings also demonstrate

Table 2. Murine models of MCD

Citation	Murine model	Key findings
Brandt et al 1990 ⁴⁵	Congenitally anemic W/W ^v mice reconstituted with bone marrow cells were transduced with a retroviral vector that introduced the coding sequences of murine IL-6 into mouse hematopoietic cells.	Mice demonstrated MCD features, including anemia, transient granulocytosis, hypoalbuminemia, plasma cell infiltration, and polyclonal hypergammaglobulinemia, with marked splenomegaly and peripheral lymphadenopathy
Screpanti et al 1995 ⁴⁷	<i>C/EBPβ</i> knockout mice were generated by gene targeting through homologous recombination at the endogenous <i>C/EBPβ</i> locus.	<i>C/EBPβ</i> ^{-/-} mice develop a syndrome similar to mice overexpressing IL-6 and very similar to human MCD, with splenomegaly, lymphadenopathy, and enhanced hematopoiesis. There was also dysfunction of humoral, innate and cellular immunity, including defective activation of splenic macrophages, impaired IL-12 production, increased susceptibility to <i>Candida albicans</i> , and T-helper cell dysfunction.
Katsume et al 2002 ⁴⁶	Transgenic mice carrying human IL-6 cDNA fused with a murine major histocompatibility class I promoter were administered with an anti-IL-6 receptor antibody.	The untreated transgenic mice developed plasmacytosis, mesangial proliferative glomerulonephritis, leukocytosis, thrombocytosis, anemia, and other laboratory abnormalities. Treatment prevented all symptoms and extended the lifetime of most mice.

that iMCD histopathology and symptomatology are secondary to hypercytokinemia.⁵⁰

IL-6 is a multifunctional cytokine produced by various cells, including mesothelial cells, monocytes, macrophages, lymphocytes, fibroblasts, endothelial cells, mesangial cells, and a variety of tumor cells. IL-6 induces plasmacytosis and hypergammaglobulinemia, VEGF secretion, thrombocytosis, acute inflammatory protein production in the liver, and activation of macrophages and T cells.⁸ IL-6 may also be responsible for autoimmune phenomena in iMCD, such as hemolytic anemia, by inducing expansion of autoantibody-producing, CD5-positive B lymphocytes.^{51,52}

Several other cytokines may play important roles in iMCD pathogenesis as well. There are iMCD cases with low or moderately elevated systemic levels of IL-6, and others who do not respond adequately to anti-IL-6 therapy, suggesting that other pathways and cytokines may contribute to pathogenesis.⁵³ Considering the redundancy of cytokine roles, it is certainly plausible that the hypersecretion of similar cytokines could result in a related clinical phenotype.

VEGF, IL-1, and tumor necrosis factor α (TNF- α) are also frequently elevated in iMCD.⁵⁴⁻⁵⁶ VEGF, which promotes cell survival, angiogenesis, and vascular permeability, is often elevated in parallel with iMCD symptoms.⁵⁶ Elevated systemic VEGF levels typically decrease in iMCD cases following anti-IL-6 treatment, suggesting that VEGF release is downstream of IL-6. However, VEGF's role has not been fully elucidated in iMCD, and it may be upstream of IL-6 in some patients as it is in the related disease POEMS syndrome.⁵⁷

IL-1, which is upstream of IL-6 in the proinflammatory cascade and leads to IL-6 production through nuclear factor (NF)- κ B signaling, was expressed at elevated levels in 5 cases of HHV-8 unknown MCD.^{54,58,59} Additionally, a patient who did not respond to anti-IL-6 therapy had a complete response to anti-IL-1 therapy in 1 case report.⁶⁰ IL-1 and IL-6 may both be overexpressed in iMCD because of a common aberrant upstream regulator, such as NF- κ B, or up-regulated IL-1, in turn inducing IL-6.⁶¹

Other cofactors reportedly elevated in MCD include epidermal growth factor receptor, cyclooxygenase-2, IL-8, IL-5, macrophage colony stimulating factor, soluble IL-2 receptor, B-lymphocyte stimulator, IL-2, and serum soluble Fas ligand.^{2,55,62-68} Comprehensive cytokine panels and proteomic studies are needed to further elucidate the cytokine network.

Candidate activated pathways

It is unclear which pathways are responsible for iMCD hypercytokinemia. Candidate pathways include transcription factors upstream and downstream of the IL-6 gene, such as NF- κ B, CCAAT/enhancer binding protein β (C/EBP β), and Janus kinases/signal transducer and activator of transcription 3, and aberrantly activated kinases known to cause hypercytokinemia in related diseases. NF- κ B is the primary transcription factor for several of the cytokines commonly elevated in iMCD, and it has been proposed as one of the important dysregulated pathways in iMCD pathogenesis.⁶¹ Mutations in the gene responsible for turning off NF- κ B transcription result in auto-inflammatory disorders that demonstrate episodic bouts of intense inflammation.⁶⁹ Also, knocking out C/EBP β in mice causes a lymphoproliferative disease nearly identical to iMCD, and symptoms can be reversed with IL-6 blockade.⁷⁰ The elevated IL-6 secretion in these mice, which was not anticipated, was hypothesized to occur because of unopposed signal transducer and activator of transcription 3 signaling or preferential expansion of type 2 helper (T_H2) pools.⁷⁰ A candidate aberrantly activated kinase is the anaplastic lymphoma kinase (*ALK*) gene, which drives the growth of inflammatory myofibroblastic tumors and causes a Castleman-like syndrome following a translocation event.⁴⁹ Further studies using gene expression profiling and genome-wide discovery studies using next-generation sequencing are needed to reveal the activated pathways that drive iMCD hypercytokinemia.

Genetic background

Although iMCD does not follow classical Mendelian inheritance patterns and iMCD typically presents at older ages than in monogenic diseases, a few recent studies and observations suggest that the underlying genetic background may contribute to iMCD pathogenesis. We have recently observed 2 familial cases of iMCD and are currently searching for a common genetic aberration (F.v.R., unpublished data, September 13, 2013). Additionally, Stone et al identified an increased frequency of 2 single nucleotide polymorphisms in the IL-6 receptor among 58 iMCD patients compared with 50 controls. They also found higher levels of soluble IL-6 receptor among individuals with these polymorphisms.³⁷ Polymorphisms within cytokine genes can influence cytokine expression and are associated with other inflammatory diseases, such as systemic-onset juvenile chronic arthritis.⁷¹ Additionally, a case of Castleman disease was heterozygous for

Table 3. Genetic aberrations reported to be associated with iMCD and iMCD-like diseases

Citation	Gene	Key findings
Nakamura et al 1993 ²⁷	<i>IL-6</i> (presumed by authors)	Somatic translocation [46,XY,t(7;14)(p22;q22)] at the <i>IL-6</i> gene locus (7p21-22) in lymph node cells in 1 case report
Gleason et al 2008 ⁴⁹	<i>ALK</i>	Somatic <i>ALK</i> -mutated tumors secrete cytokines and cause MCD-like features
Kone-Paut et al 2009 ⁷³	<i>MEFV</i>	Heterozygous for a germ-line <i>MEFV</i> gene mutation in one CD case
Stone et al 2013 ³⁷	<i>IL-6</i> receptor	SNP present in 49% of 58 iMCD cases vs 33% of 50 controls ($P = .0175$)

a Mediterranean fever (*MEFV*) gene mutation, which promotes the acute phase response and the development of severe vasculitis, periodic fevers, and autoimmune disorders.^{72,73} (Table 3, genetic aberrations reported to be associated with iMCD and iMCD-like diseases). Genome-wide studies and next-generation sequencing are needed to elucidate the existence of a predisposing genetic background in patients with iMCD.

Hypercytokine-secreting cell

The cell type responsible for initiating iMCD hypercytokinemia by secreting IL-6 and other proinflammatory cytokines has not been elucidated and may differ between patients and histological subtypes. These “hypercytokine-secreting cells” could exist anywhere in the body. Candidate cell types include macrophages, FDCs, fibroblasts, B cells, T cells, plasma cells, and cytokine-producing tumor cells. The frequent classification of iMCD as a lymphoproliferative disorder has caused confusion within the medical community, because it suggests that there are cytogenetically abnormal lymphocytes, which has not been shown and may lead to improper management.

B cells and plasma cells are typically implicated as the pathologic overproducers of IL-6 in the literature.^{61,74} Yoshizaki et al’s seminal paper is often cited, in which IL-6 expression came from blastoid B cells in the germinal center in 1 UCD lymph node and 1 HIV-negative, HHV-8 unknown MCD lymph node.⁷⁵ However, subsequent studies have not consistently demonstrated IL-6 expression by B cells and plasma cells. Leger-Ravet et al and Ishiyama et al reported IL-1β and IL-6 expression by monocytes, macrophages, FDCs, lymphocytes, and endothelial cells, but not plasma cells in HIV-negative, HHV-8 unknown MCD lymph nodes.^{59,64} A recent study of HIV-negative, HHV-8 unknown MCD lymph nodes found IL-6 expression by plasma cells, endothelial cells, macrophages, and FDCs.⁷⁶ Chang et al’s recent finding of monoclonality in all 4 iMCD cases (3 HV and 1 PC) suggests that stromal cells, such as myoid cells and follicular dendritic cells, may be the pathologic cell in iMCD.²⁸ Activated T cells may play an important role as well, as soluble IL-2 receptor levels are often elevated and cyclosporine A is an effective monotherapy in a small number of cases.^{2,77} Further studies involving in situ hybridization for IL-6 mRNA and investigations of stromal cell monoclonality in iMCD are needed.

Unifying model of iMCD pathogenesis

Considering the heterogeneity of clinical, histological, and laboratory presentations of iMCD, we propose that iMCD represents

a common end point that can be reached through multiple processes, each involving immune dysregulation and a common pathway of elevated proinflammatory cytokine release. We hypothesize that 1 or more of the following 3 candidate processes are responsible for driving iMCD hypercytokinemia: (1) autoimmune/autoinflammatory mechanisms via autoantibody antigenic stimulation or a germ-line genetic aberration in innate immune regulation (systemic inflammatory disease hypothesis), (2) ectopic cytokine secretion by malignant or benign tumor cells within the lymph nodes or extranodal (paraneoplastic syndrome hypothesis), and (3) viral signaling by a non-HHV-8 virus (virally driven hypothesis). We describe these hypothesized mechanisms below and present a model (Figure 3).

Systemic inflammatory disease hypothesis

There are 2 mechanisms that may drive iMCD hypercytokinemia under the systemic inflammatory disease hypothesis. Autoantibodies stimulate antigen-presenting cells (eg, FDCs and macrophages) in the lymph node to release proinflammatory cytokines (eg, IL-6, IL-1, and/or TNF-α). Then, the cytokine signals via a transcription factor in an as-yet-undetermined hypercytokine-secreting cell resulting in proinflammatory hypercytokinemia, downstream iMCD symptoms, and perpetuation of proinflammatory signaling. Alternatively, auto-inflammatory mechanisms involving a germ-line aberration in a gene of innate immunity (eg, IL-6 promoter polymorphism, mutation in NF-κB regulatory gene, or inability of natural killer cells or cytotoxic T cells to lyse activated inflammatory cells⁷⁸) may drive iMCD hypercytokinemia. The following lines of evidence support the systemic inflammatory disease hypothesis:

1. Autoimmune diseases can demonstrate histopathology identical to iMCD. Nearly all lymph nodes of rheumatoid arthritis patients and 15% to 30% of systemic lupus erythematosus (SLE) lymph nodes display MCD-like histopathology.^{3,22-24}
2. IMCD involves intense episodes of inflammation that are clinically similar to autoimmune and autoinflammatory diseases, such as SLE, adult-onset Still’s disease, periodic fever syndromes, and hemophagocytic syndromes.^{3,78}
3. Immunosuppressive therapies and monotherapy with anti-cytokine antibodies can bring about sustained remissions.^{2,12}
4. Several connective tissue diseases, such as rheumatoid arthritis, Sjogren syndrome, SLE, and myasthenia gravis have been reported to be diagnosed concurrently with iMCD.³ The clinical and laboratory features leading to these diagnoses may have been driven by iMCD.
5. Autoimmune manifestations and autoantibodies are frequently found in iMCD when no other autoimmune disease is diagnosed.¹⁴
6. Germ-line mutations in 2 important inflammatory genes have been reported in iMCD.^{37,73}

Further investigation is needed to determine if at least a cohort of iMCD cases are driven by systemic inflammatory disease mechanisms. The discovery of autoreactive T cells and pathogenic autoantibodies would support iMCD being an autoimmune disorder. Priorities for investigators include determining whether iMCD autoantibodies trigger the IL-6 hypersecretion or are secondary to iMCD immune dysregulation and also searching for aberrations in cells responsible for regulating inflammation.

Paraneoplastic syndrome hypothesis

The paraneoplastic syndrome hypothesis posits that a somatic mutation causes malignant or benign tumor cells inside or outside




Figure 3. Proposed model of iMCD pathogenesis. Three hypothesized mechanisms may be responsible for iMCD proinflammatory hypercytokinemia. (1) The systemic inflammatory disease hypothesis involves (1a) autoantibodies triggering proinflammatory cytokine release by antigen-presenting cells that induce the hypercytokine-secreting cell to release IL-6; (1b/c) an error in kinase or inhibitory signaling in an antigen-presenting cell or other hypercytokine-secreting cell causing IL-6 secretion, or (1d) a defect in the regulation of activated inflammatory cells. Systemic inflammation is perpetuated by positive feedback of IL-6 and possibly further autoantibody stimulation. (2) The paraneoplastic syndrome hypothesis involves a somatic mutation in benign or malignant cells inside or outside of the lymph node that causes constitutive proinflammatory cytokine release. (3) The virally driven hypothesis involves a non-HHV-8 virus (ex: EBV, HHV-6) signaling proinflammatory cytokines. Regardless of the etiology, the proinflammatory hypercytokinemia is the common pathway that results in the subsequent clinical and histopathological features of iMCD. AAB, autoantibodies; AIHA, autoimmune hemolytic anemia; AIT, autoimmune thrombocytopenia; LAD, lymphadenopathy; PMN, polymorphous neutrophil.

of the lymph node to release iMCD cytokines. A small population of monoclonal stromal cells in multiple lymph nodes or in a sentinel node could be the hypercytokine-secreting cells that trigger an enormous reactive response, such as has been observed in Hodgkin lymphoma and recently in 4 cases of iMCD.²⁸ The following 4 lines of evidence support the paraneoplastic syndrome hypothesis:

1. Monoclonality was observed in most HV-UCD cases and 4 of 4 recently tested iMCD cases (3 HV-iMCD and 1 PC-iMCD). These cases demonstrated polyclonal lymphocytes, so the monoclonal cells were assumed to be stromal.²⁸ Monoclonality is an early step in the neoplastic process, and the subsequent development of stromal tumors have been frequently reported in HV-UCD.¹ The somatic mutations responsible for monoclonality could certainly also cause the cytokine secretion that drives iMCD.

2. POEMS syndrome, a paraneoplastic syndrome that can demonstrate significant clinical and histopathological overlap with iMCD, is driven predominantly by VEGF secretion by malignant plasma cells. iMCD pathology and symptoms may be due to cytokine release by as-yet-undetermined monoclonal cells, such as monoclonal plasma cells in POEMS.

3. Solid malignancies can cause iMCD symptoms and histopathology in neighboring lymph nodes through IL-6 release that resolves with the excision of these tumors.³⁶ These solid tumors may be present, but undetected at the time of diagnosis, in more cases of iMCD.

4. Hematologic malignancies are diagnosed at an increased frequency within 2 years of iMCD diagnosis.⁷⁹ These malignant cells may have been present all along and actually secreted the IL-6

that was responsible for the preceding iMCD symptoms and diagnosis. For instance, 1 reported case of iMCD was subsequently found to have Hodgkin lymphoma. Review of the initial histopathology identified Reed-Sternberg cells, which were also found to secrete IL-6. The iMCD-like features disappeared with anti-IL-6 receptor blockade.⁴⁸

Alternative explanations for the frequent association between iMCD and malignancy include the possibility that iMCD is a prelymphoma that eventually transforms, excessive cytokine release promotes malignant transformation, iMCD treatments cause or increase susceptibility to secondary malignancies, or an unidentified virus may be responsible for both the iMCD and the malignancy.^{80,81} We suggest that a search for an underlying malignancy be conducted in all newly diagnosed iMCD patients. Additionally, further investigation is needed to search for monoclonal cells in iMCD lymph nodes.

Virally driven hypothesis

The virally driven hypothesis proposes that a virus other than HHV-8 is responsible for driving iMCD in a cohort of patients. The virus may directly signal for viral IL-6 or human IL-6, such as in HHV-8-associated MCD, or it may cause immune dysregulation that results in subsequent disease. The following 4 lines of evidence support the virally driven hypothesis:

1. The acute onset of intense symptoms that can be seen in a subset of patients is characteristic of a viral process.
2. The periods of waning disease activity and intermittent flares fits well with a latent viral infection that occasionally switches to lytic cycle.
3. iMCD demonstrates clinical and histopathological overlap with HHV-8-associated MCD.⁶ Furthermore, there is redundancy among lymphotropic gammaherpesviruses regarding host cell and inflammatory proteins.⁸²
4. EBV and a few other candidate viruses have been reported to occur with iMCD even though systematic viral serologies and sequencing studies have not been performed to date.³⁸⁻⁴³

Comprehensive viral serologies and deep sequencing studies are needed to identify a known or undiscovered virus that may drive iMCD.

Treatment

Three treatment strategies have been used based on our understanding of iMCD: anti-inflammatory and immunosuppressive therapies, cytotoxic elimination of cells responsible for hypercytokinemia, and blockade of IL-6 signaling with mAbs. Corticosteroids can improve symptoms during acute exacerbations of iMCD, but most patients relapse during steroid tapering.^{83,84} Immunosuppressive therapies, particularly cyclosporine A, are being used more frequently as some physicians are treating iMCD more like a systemic inflammatory disease.^{85,86} Rituximab, which is a frequent first- or second-line therapy in iMCD, is only partially effective and typically does not provide long-term disease control.⁸⁷⁻⁸⁹ Cytotoxic lymphoma-based chemotherapies (eg, cyclophosphamide, doxorubicin, vincristine, and prednisone) induce responses in a large portion of the most severely ill iMCD patients by eliminating a large portion of hypercytokine-secreting cells, but relapses are common and side effects are significant.^{90,91}

Over the last decade, treatments directly targeting IL-6 have been used. Tocilizumab, an anti-IL-6 receptor mAb that is approved to treat MCD in Japan, has demonstrated effectiveness at inducing and maintaining remission.¹³ Siltuximab, an anti-IL-6 mAb that has been submitted for approval to the US Food and Drug Administration and European Medicines Agency, demonstrated durable tumor and symptomatic response at a significantly higher rate compared with placebo in the first randomized phase 2 study in MCD (34% vs 0%; $P = .0012$).^{92,93} Both mAbs have shown clinical activity in iMCD and are potential candidates for frontline therapy. However, they require lifelong administration and are not effective in all patients. Anti-IL-6 and anti-CD-20 therapies may not be effective in all cases of iMCD, because hypercytokinemia and B-cell proliferation are 2 common products seen in iMCD but not necessarily the drivers of the underlying pathogenesis. Additional variability may be due to disease heterogeneity, misclassification or misdiagnosis, and timing of therapy.

Recently, therapeutic approaches targeting pathways upstream of IL-6 have been reported in iMCD, and these deserve further exploration, particularly for anti-IL-6 refractory patients. Bortezomib, a selective proteasome inhibitor that preferentially targets plasma cells, has lowered IL-6 levels and induced remission in 4 cases of iMCD.⁹⁴⁻⁹⁶ Bortezomib may work in iMCD via direct inhibition of NF- κ B by degrading the I κ B kinase.⁹⁷ Thalidomide, an immunomodulator that inhibits TNF- α , IL-1, IL-6, IL-12, and VEGF and stimulates T cells potentially via cereblon inhibition, has demonstrated effectiveness at inducing remission, decreasing IL-6 levels, and lowering C-reactive protein in iMCD.^{66,98,99} Anakinra, an IL-1 receptor antagonist, has also been reported to induce remission in a pediatric case of iMCD and in a patient who did not respond to anti-IL-6 therapy.^{60,100} Further elucidation of iMCD pathogenesis is urgently needed to provide additional candidate targeted therapies. The multiple therapies used, variation in scientific rigor (eg, sample size, reporting bias), and heterogeneity of reported outcomes, as well as length of follow-up, make detailed analyses of therapies in iMCD very complicated. Therefore, a synthesis of treatments used in iMCD with response and survival outcomes will be reported in a separate paper (D.C.F., C.S.N., and Amy Y. Liu, unpublished data, 2014).

Next steps

Much progress has been made in patient outcomes over the last 20 years, but confusion in the literature as outlined in this article has slowed our understanding of iMCD pathogenesis. Here, we synthesize what is known about iMCD pathogenesis, present a new subclassification system, and propose a model of iMCD pathogenesis. Investigators must fill the current gaps in our understanding of iMCD through the following urgent steps: elucidating the mechanisms responsible for the hypercytokinemia in iMCD, searching for monoclonal stromal cells or other pathological hypercytokine-secreting cell, searching for viral sequences, and identifying disease-specific biomarkers.

The Castleman Disease Collaborative Network (CDCN) was developed in August 2012 by a group of physicians and researchers to accelerate research and facilitate collaboration among the global research community. The CDCN has coordinated the largest-to-date meeting of MCD researchers and physicians, developed a database of >200 treating physicians and researchers worldwide, launched a platform for private communication and online discussion among iMCD physicians and researchers, assembled a 23-member Scientific Advisory Board of experts from around the globe, and developed an

initial scientific agenda. More information about the CDCN and a forum for iMCD physicians and researchers to communicate with one another can be accessed at www.castlemannetwork.org.

Important next steps for the field and priorities for the CDCN include developing an international consensus criterion on iMCD diagnosis, creating a patient registry with a virtual tissue repository, offering research funding, collecting patient quality-of-life data, and facilitating greater collaboration with rheumatologists, immunologists, and virologists. With these steps in motion and continued engagement from the global iMCD physician and researcher community, the potential for progress in our understanding and treatment of iMCD is great.

Acknowledgments

The authors thank Drs Arthur Rubenstein, Vera Krymskaya, and Ed Behrens for review and insight. They also wish to thank the members of the CDCN Scientific Advisory Board.

References

1. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. *Adv Anat Pathol*. 2009;16(4):236-246.
2. Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric castleman's disease: a retrospective study of 21 Japanese patients at a single institute. *J Clin Exp Hematop*. 2013;53(1):69-77.
3. Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. *Curr Opin Rheumatol*. 2012;24(1):76-83.
4. Mehra M, Cossrow N, Stellhorn RA, Vermeulen J, Desai A, Munshi NC. Use of a claims database to characterize and estimate the incidence of Castleman's disease [abstract]. *Blood*. 2012;120(21). Abstract 4253.
5. Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. *Pathol Int*. 2001;51(9):671-679.
6. Dossier A, Meignin V, Fieschi C, Boutboul D, Oksenhendler E, Galicier L. Human herpesvirus 8-related Castleman disease in the absence of HIV infection. *Clin Infect Dis*. 2013;56(6):833-842.
7. Leroy S, Moshous D, Cassar O, et al. Multicentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic review. *Pediatrics*. 2012;129(1):e199-e203.
8. Kishimoto T. IL-6: from its discovery to clinical applications. *Int Immunol*. 2010;22(5):347-352.
9. Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. *Oncologist*. 2011;16(9):1316-1324.
10. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman's disease. *Am J Hematol*. 2012;87(11):997-1002.
11. Peterson BA, Frizzera G. Multicentric Castleman's disease. *Semin Oncol*. 1993;20(6):636-647.
12. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. *Clin Cancer Res*. 2013;19(13):3659-3670.
13. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood*. 2005;106(8):2627-2632.
14. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. *Clin Adv Hematol Oncol*. 2010;8(7):486-498.
15. Bower M. How I treat HIV-associated multicentric Castleman disease. *Blood*. 2010;116(22):4415-4421.
16. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. *J Infect Dis*. 1997;175(5):1198-1201.
17. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. *N Engl J Med*. 1954;251(10):396-400.
18. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. *Am J Clin Pathol*. 1978;69(1):86-90.
19. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. *Acta Oncol*. 2004;43(8):698-704.
20. Menke DM, DeWald GW. Lack of cytogenetic abnormalities in Castleman's disease. *South Med J*. 2001;94(5):472-474.
21. Weisenburger DD. Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen. *Am J Surg Pathol*. 1988;12(3):176-181.
22. Kojima M, Motoori T, Asano S, Nakamura S. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. *Pathol Res Pract*. 2007;203(6):423-431.
23. Kojima M, Motoori T, Nakamura S. Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. *Biomed Pharmacother*. 2006;60(10):663-672.
24. Kojima M, Nakamura S, Morishita Y, et al. Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. *Pathol Int*. 2000;50(4):304-312.
25. Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. *Am J Clin Pathol*. 1994;101(3):290-295.
26. Al-Maghrahi J, Kamel-Reid S, Bailey D. Immunoglobulin and T-cell receptor gene rearrangement in Castleman's disease: molecular genetic analysis. *Histopathology*. 2006;48(3):233-238.
27. Nakamura H, Nakaseko C, Ishii A, et al. [Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6]. *Rinsho Ketsueki*. 1993;34(2):212-217.
28. Chang KC, Wang YC, Hung LY, et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease. *Mod Pathol*. 2013.
29. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. *Br J Haematol*. 2005;129(1):3-17.
30. Fajgenbaum D, Rosenbach M, van Rhee F, Nasir A, Reutter J. Eruptive cherry hemangiomas associated with multicentric Castleman disease: a case report and diagnostic clue. *JAMA Dermatol*. 2013;149(2):204-208.
31. Ahmed B, Tschien JA, Cohen PR, et al. Cutaneous castleman's disease responds to anti interleukin-6 treatment. *Mol Cancer Ther*. 2007;6(9):2386-2390.
32. Zhai S. Polynesian variant of idiopathic multicentric Castleman disease [abstract]. *Blood*. 2013;122(21). Abstract 5127.
33. Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). *J Clin Exp Hematop*. 2013;53(1):57-61.
34. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. *Neurology*. 1984;34(6):712-720.

This work was supported in part by funding from the Charles and Clydene Scharlau Chair for Hematological Malignancies Research.

Authorship

Contribution: D.C.F performed the review, analyzed the results of the review, and wrote the manuscript; C.S.N. created the figures and wrote the manuscript; and F.v.R. analyzed the results of the review and wrote the manuscript.

Conflict-of-interest disclosure: D.C.F. is on an advisory board for Janssen Pharmaceuticals. F.v.R. receives research funding from Janssen Pharmaceuticals. The remaining author declares no competing financial interests.

Correspondence: David C. Fajgenbaum, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Smilow Center for Translational Research, 3400 Civic Center Blvd, Bldg 421, Room 12-122, Philadelphia, PA 19104-5160; e-mail: david.fajgenbaum.wg15@wharton.upenn.edu

35. Soubrier MJ, Dubost JJ, Sauvezie BJ; French Study Group on POEMS Syndrome. POEMS syndrome: a study of 25 cases and a review of the literature. *Am J Med*. 1994;97(6):543-553.
36. Morishima A, Marui A, Shimamoto T, Saji Y, Nishina T, Komeda M. A case of interleukin-6-producing cardiac myxoma resembling multicentric Castleman's disease. *J Thorac Cardiovasc Surg*. 2009;138(2):499-501.
37. Stone K, Woods E, Szmania SM, et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. *PLoS ONE*. 2013; 8(1):e54610.
38. Barozzi P, Luppi M, Masini L, et al. Lymphotropic herpes virus (EBV, HHV-6, HHV-8) DNA sequences in HIV negative Castleman's disease. *Clin Mol Pathol*. 1996;49(4):M232-M235.
39. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. *Cancer*. 1999;85(3): 706-717.
40. Chen CH, Liu HC, Hung TT, Liu TP. Possible roles of Epstein-Barr virus in Castleman disease. *J Cardiothorac Surg*. 2009;4:31.
41. Jones EL, Crocker J, Gregory J, Guibarra M, Curran RC. Angiofollicular lymph node hyperplasia (Castleman's disease): an immunohistochemical and enzyme-histochemical study of the hyaline-vascular form of lesion. *J Pathol*. 1984;144(2):131-147.
42. Murray PG, Deacon E, Young LS, et al. Localization of Epstein-Barr virus in Castleman's disease by in situ hybridization and immunohistochemistry. *Hematol Pathol*. 1995; 9(1):17-26.
43. Yuan XG, Chen FF, Zhu YM, Hu W, Zhao XY, Jin J. High prevalence of hepatitis B virus infection in HIV-negative Castleman's disease. *Ann Hematol*. 2012;91(6):857-861.
44. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. *J Clin Oncol*. 2010;28(23):3701-3708.
45. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. *J Clin Invest*. 1990;86(2): 592-599.
46. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. *Cytokine*. 2002;20(6): 304-311.
47. Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. *EMBO J*. 1995;14(9):1932-1941.
48. Momoi A, Kojima M, Sakai T, et al. IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case. *Int J Hematol*. 2013;97(2): 275-279.
49. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? *J Clin Pathol*. 2008;61(4):428-437.
50. van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. *Blood*. 1994;84(5):1434-1441.
51. Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. *Histopathology*. 1989; 14(4):333-346, discussion 429-432.
52. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. *Am J Clin Pathol*. 1996;105(3): 268-276.
53. Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia—a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? *J Clin Exp Hematop*. 2013;53(1):79-85.
54. Gherardi RK, Bélec L, Fromont G, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. *Blood*. 1994;83(9):2587-2593.
55. Lee M, Hirokawa M, Matuoka S, et al. Multicentric Castleman's disease with an increased serum level of macrophage colony-stimulating factor. *Am J Hematol*. 1997;54(4): 321-323.
56. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. *Br J Haematol*. 1999; 104(3):482-485.
57. Wang X, Ye S, Xiong C, Gao J, Xiao C, Xing X. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. *Jpn J Clin Oncol*. 2011;41(10): 1221-1224.
58. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol*. 2009;27:519-550.
59. Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. *Blood*. 1991;78(11): 2923-2930.
60. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). *Mol Cancer Ther*. 2010;9(6):1485-1488.
61. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. *Oncologist*. 2011;16(4):497-511.
62. De Marchi G, De Vita S, Fabris M, Scott CA, Ferraccioli G. Systemic connective tissue disease complicated by Castleman's disease: report of a case and review of the literature. *Haematologica*. 2004;89(4):ECR03.
63. Ishii T, Tatekawa T, Koseto M, et al. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5. *Eur J Haematol*. 2003;70(2): 115-118.
64. Ishiyama T, Nakamura S, Akimoto Y, et al. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease. *Br J Haematol*. 1994; 86(3):483-489.
65. Liu J, Han S, Ding J, Wu K, Miao J, Fan D. COX2-related multicentric mixed-type Castleman's disease in a young man. *Nat Clin Pract Oncol*. 2005;2(7):370-375, quiz 376.
66. Miltenyi Z, Toth J, Gonda A, Tar I, Remenyik E, Illes A. Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. *Pathol Oncol Res*. 2009; 15(3):375-381.
67. Sun X, Chang KC, Abruzzo LV, Lai R, Younes A, Jones D. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. *Hum Pathol*. 2003;34(9): 835-840.
68. Takubo T, Ohkura H, Kumura T, et al. Lymphoma in Castleman's disease, acute lymphocytic leukemia, adult T-cell leukemia and cutaneous T-cell lymphoma accompanied with high serum soluble Fas ligand levels. *Haematologia (Budap)*. 2000;30(1):23-26.
69. Masters SL, Simon A, Aksentjevich I, Kastner DL. Horror autinflammatus: the molecular pathophysiology of autoinflammatory disease (*). *Annu Rev Immunol*. 2009;27:621-668.
70. Alonzi T, Gorgoni B, Screpanti I, Gulino A, Poli V. Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation. *Immunobiology*. 1997;198(1-3):144-156.
71. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J Clin Invest*. 1998; 102(7):1369-1376.
72. Hatemi G, Masatlioglu S, Gogus F, Ozdogan H. Necrotizing vasculitis associated with familial Mediterranean fever. *Am J Med*. 2004;117(7): 516-519.
73. Koné-Paut I, Hentgen V, Guillaume-Czitrom S, Compeyrot-Lacassagne S, Tran TA, Toubou I. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. *Rheumatology (Oxford)*. 2009;48(7):840-842.
74. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. *N Engl J Med*. 1994; 330(9):602-605.
75. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. *Blood*. 1989; 74(4):1360-1367.
76. Lai YM, Li M, Liu CL, et al. [Expression of interleukin-6 and its clinicopathological significance in Castleman's disease]. *Zhonghua Xue Ye Xue Za Zhi*. 2013;34(5):404-408.
77. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. *Cancer Res*. 2006;66(2): 605-612.
78. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. *Am J Clin Pathol*. 2013;139(6): 713-727.
79. Larroche C, Cacoub P, Soulier J, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. *Am J Hematol*. 2002;69(2): 119-126.
80. Maione D, Di Carlo E, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. *EMBO J*. 1998;17(19):5588-5597.
81. Zhu C-G, Zhang Q-Z, Zhu M, et al. A case report of syndrome of inappropriate antidiuretic hormone secretion with Castleman's disease and lymphoma. *BMC Endocr Disord*. 2013;13(1):19.
82. Yokoi T, Miyawaki T, Yachie A, Kato K, Kasahara Y, Taniguchi N. Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. *Immunology*. 1990; 70(1):100-105.
83. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. *J Clin Oncol*. 1985; 3(9):1202-1216.

84. Tsukamoto Y, Hanada N, Nomura Y, et al. Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. *Am J Nephrol*. 1991;11(5):430-436.
85. Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin a : a case report. *J Clin Exp Hematop*. 2013;53(1):95-99.
86. Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly : a clinical report of five cases. *J Clin Exp Hematop*. 2013;53(1): 63-68.
87. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. *Ann Hematol*. 2003; 82(12):766-768.
88. Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. *Eur J Haematol*. 2006;76(2): 119-123.
89. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. *Am J Hematol*. 2005; 78(4):302-305.
90. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. *Cancer*. 2001;92(3):670-676.
91. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. *Ann Intern Med*. 1998;128(8):657-662.
92. Williams SC. First IL-6-blocking drug nears approval for rare blood disorder. *Nat Med*. 2013; 19(10):1193.
93. Wong R, Casper C, Munshi N, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman's disease [abstract]. *Blood*. 2013; 122(21). Abstract 505.
94. Hess G, Wagner V, Kreft A, Heussel CP, Huber C. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. *Br J Haematol*. 2006;134(5):544-545.
95. Khan AA, Siraj F, Bhargava M, Aggarwal S. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib. *BMJ Case Rep*; bcr-2012.
96. Sobas MA, Alonso Vence N, Diaz Arias J, Bendaña Lopez A, Fraga Rodriguez M, Bello Lopez JL. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). *Ann Hematol*. 2010;89(2): 217-219.
97. Juvekar A, Manna S, Ramaswami S, et al. Bortezomib induces nuclear translocation of I κ B α resulting in gene-specific suppression of NF- κ B—dependent transcription and induction of apoptosis in CTCL. *Mol Cancer Res*. 2011; 9(2):183-194.
98. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. *Leukemia*. 2012;26(11): 2326-2335.
99. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. *Am J Hematol*. 2006;81(4):303-304.
100. Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Koné-Paut I. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. *J Pediatr Hematol Oncol*. 2008;30(12):920-924.